Peak Bio (PKBO) Competitors

$0.0096

0.00 (0.00%)

(As of 07/26/2024 ET)

Stock Analysis Chart Competitors Earnings Financials Headlines SEC Filings Trends

PKBO vs. ACORQ, IGNY, GNCAQ, GNCA, VECT, OPFI, AMGN, GILD, MRNA, and BIIB

Should you be buying Peak Bio stock or one of its competitors? The main competitors of Peak Bio include Acorda Therapeutics (ACORQ), Ignyte Acquisition (IGNY), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), VectivBio (VECT), OppFi (OPFI), Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), and Biogen (BIIB).

Peak Bio vs.

Peak Bio (NASDAQ:PKBO) and Acorda Therapeutics (NASDAQ:ACORQ) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, community ranking, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

: Peak Bio has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500. Comparatively, Acorda Therapeutics has a beta of 1.67, indicating that its share price is 67% more volatile than the S&P 500.
: Peak Bio has a net margin of 0.00% compared to Acorda Therapeutics' net margin of -227.75%. Peak Bio's return on equity of 0.00% beat Acorda Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Peak Bio N/A N/A N/A
Acorda Therapeutics -227.75% -2,206.93% -114.39%
: Peak Bio has higher earnings, but lower revenue than Acorda Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Peak Bio $610K 0.36 -$13.09M N/A N/A
Acorda Therapeutics $117.63M 0.00 -$252.85M -$212.09 0.00
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Peak Bio
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
Acorda Therapeutics
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
: In the previous week, Peak Bio's average media sentiment score of 0.00 equaled Acorda Therapeutics'average media sentiment score.
Company Overall Sentiment
Peak Bio Neutral
Acorda Therapeutics Neutral
: 12.7% of Acorda Therapeutics shares are held by institutional investors. 19.9% of Peak Bio shares are held by insiders. Comparatively, 2.6% of Acorda Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
: Peak Bio received 1 more outperform votes than Acorda Therapeutics when rated by MarketBeat users.
Company Underperform Outperform
Peak Bio Outperform Votes
1
100.00%
Underperform Votes
No Votes
Acorda Therapeutics N/A N/A

Company	Net Margins	Return on Equity	Return on Assets
Peak Bio	N/A	N/A	N/A
Acorda Therapeutics	-227.75%	-2,206.93%	-114.39%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Peak Bio	$610K	0.36	-$13.09M	N/A	N/A
Acorda Therapeutics	$117.63M	0.00	-$252.85M	-$212.09	0.00

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Peak Bio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Acorda Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Company	Overall Sentiment
Peak Bio	Neutral
Acorda Therapeutics	Neutral

Company	Underperform	Outperform
Peak Bio	Outperform Votes 1 100.00%	Underperform Votes No Votes
Acorda Therapeutics	N/A	N/A

Summary

Peak Bio beats Acorda Therapeutics on 7 of the 10 factors compared between the two stocks.

Ad Unstoppable Prosperity

“Generational Bull Run” Incoming

LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.

You can find out what they are by clicking here now.

Get Peak Bio News Delivered to You Automatically

PKBO vs. The Competition

Export to Excel

Metric	Peak Bio	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$222,000.00	$3.06B	$5.31B	$8.19B
Dividend Yield	N/A	2.05%	2.72%	3.96%
P/E Ratio	N/A	27.86	152.08	18.37
Price / Sales	0.36	346.99	2,071.74	88.82
Price / Cash	N/A	181.29	35.89	34.13
Price / Book	-0.02	4.08	4.95	4.51
Net Income	-$13.09M	-$44.60M	$112.29M	$216.36M
7 Day Performance	N/A	7.01%	2.73%	1.82%
1 Month Performance	N/A	11.74%	6.97%	7.09%
1 Year Performance	N/A	1.96%	11.22%	4.88%

Peak Bio Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACORQ Acorda Therapeutics	0 of 5 stars 0.00 / 5 stars	$0.07 -29.0%	N/A	N/A	$91,000.00	$117.63M	0.00	102	Gap Down
IGNY Ignyte Acquisition	0 of 5 stars 0.00 / 5 stars	$0.01 flat	N/A	N/A	$70,000.00	N/A	0.00	N/A
GNCAQ Genocea Biosciences	0 of 5 stars 0.00 / 5 stars	N/A	N/A	N/A	$6,000.00	$1.64M	0.00	74	News Coverage
GNCA Genocea Biosciences	0 of 5 stars 0.00 / 5 stars	N/A	N/A	N/A	$6,000.00	$1.91M	0.00	70
VECT VectivBio	0 of 5 stars 0.00 / 5 stars	$16.85 flat	N/A	N/A	$0.00	$27.34M	0.00	30	High Trading Volume
OPFI OppFi	0.1789 of 5 stars 0.18 / 5 stars	$4.17 +4.5%	$4.25 +1.9%	+107.5%	$463.95M	$515.92M	69.51	570
AMGN Amgen	4.4984 of 5 stars 4.50 / 5 stars	$334.85 +0.2%	$312.63 -6.6%	+42.4%	$179.62B	$28.19B	47.84	26,700	Short Interest ↑ Analyst Revision
GILD Gilead Sciences	4.757 of 5 stars 4.76 / 5 stars	$77.01 +0.7%	$81.81 +6.2%	-0.2%	$95.94B	$27.12B	213.92	18,000	Options Volume Analyst Revision
MRNA Moderna	3.2458 of 5 stars 3.25 / 5 stars	$122.11 +1.4%	$133.88 +9.6%	+1.2%	$46.80B	$6.85B	-7.79	5,600	Upcoming Earnings Insider Selling
BIIB Biogen	4.7586 of 5 stars 4.76 / 5 stars	$211.17 -7.2%	$284.22 +34.6%	-20.4%	$30.75B	$9.84B	26.36	7,570	Upcoming Earnings Analyst Forecast Short Interest ↑ Gap Down